IKENA ONCOLOGY INC (IKNA) Stock Price, Quote, News and Overview
NASDAQ:IKNA - Nasdaq - US45175G1085 - Common Stock - Currency: USD
IKNA Quote, Performance and Key Statistics
1.13
+0.05 (+4.63%)
The current stock price of IKNA is 1.13 USD. In the past month the price increased by 6.6%. In the past year, price decreased by -12.4%.
IKNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 53.38 | 696.37B | ||
| JNJ | JOHNSON & JOHNSON | 15.35 | 371.06B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.85 | 291.96B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.08 | 214.69B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.16 | 209.49B | ||
| MRK | MERCK & CO. INC. | 9.75 | 191.17B | ||
| PFE | PFIZER INC | 6.94 | 126.36B | ||
| SNY | SANOFI-ADR | 13.03 | 122.16B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.33 | 94.53B | ||
| GSK | GSK PLC-SPON ADR | 6.69 | 74.10B | ||
| ZTS | ZOETIS INC | 26.46 | 71.04B | ||
| HLN | HALEON PLC-ADR | 21.92 | 48.43B |
Related stock screener links
About IKNA
Company Profile
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
Company Info
IKENA ONCOLOGY INC
50 Northern Ave.
Boston MASSACHUSETTS 02210 US
CEO: Mark Manfredi
Employees: 10
Phone: 18573438292
IKENA ONCOLOGY INC / IKNA FAQ
What is the stock price of IKENA ONCOLOGY INC today?
The current stock price of IKNA is 1.13 USD. The price increased by 4.63% in the last trading session.
What is the ticker symbol for IKENA ONCOLOGY INC stock?
The exchange symbol of IKENA ONCOLOGY INC is IKNA and it is listed on the Nasdaq exchange.
On which exchange is IKNA stock listed?
IKNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IKENA ONCOLOGY INC stock?
9 analysts have analysed IKNA and the average price target is 3.06 USD. This implies a price increase of 170.8% is expected in the next year compared to the current price of 1.13. Check the IKENA ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IKENA ONCOLOGY INC worth?
IKENA ONCOLOGY INC (IKNA) has a market capitalization of 61.73M USD. This makes IKNA a Micro Cap stock.
How many employees does IKENA ONCOLOGY INC have?
IKENA ONCOLOGY INC (IKNA) currently has 10 employees.
What are the support and resistance levels for IKENA ONCOLOGY INC (IKNA) stock?
IKENA ONCOLOGY INC (IKNA) has a resistance level at 1.26. Check the full technical report for a detailed analysis of IKNA support and resistance levels.
Should I buy IKENA ONCOLOGY INC (IKNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IKNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IKNA, evaluating the profitability, health, valuation and growth aspects
- IKENA ONCOLOGY INC (IKNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IKENA ONCOLOGY INC (IKNA) Sales and EPS estimates to see what analysts future expectations are.
- IKENA ONCOLOGY INC (IKNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IKENA ONCOLOGY INC (IKNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- IKENA ONCOLOGY INC (IKNA) Stock Chart to make your own analysis
- IKENA ONCOLOGY INC (IKNA) Latest news and press-releases to stay up to date.
Does IKENA ONCOLOGY INC (IKNA) stock pay dividends?
IKNA does not pay a dividend.
When does IKENA ONCOLOGY INC (IKNA) report earnings?
IKENA ONCOLOGY INC (IKNA) will report earnings on 2025-05-12, before the market open.
What is the Price/Earnings (PE) ratio of IKENA ONCOLOGY INC (IKNA)?
IKENA ONCOLOGY INC (IKNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.01).
What is the Short Interest ratio of IKENA ONCOLOGY INC (IKNA) stock?
The outstanding short interest for IKENA ONCOLOGY INC (IKNA) is 0.37% of its float. Check the ownership tab for more information on the IKNA short interest.
IKNA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IKNA. When comparing the yearly performance of all stocks, IKNA is a bad performer in the overall market: 76.26% of all stocks are doing better.
IKNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IKNA. IKNA has a great financial health rating, but its profitability evaluates not so good.
IKNA Financial Highlights
Over the last trailing twelve months IKNA reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS increased by 40.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.79% | ||
| ROE | -39.1% | ||
| Debt/Equity | 0 |
IKNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to IKNA. The Buy consensus is the average rating of analysts ratings from 9 analysts.